Although the majority of patients with metastatic non–small-cell lung cancer (mNSCLC) lacking a detectable targetable mutation will receive pembrolizumab-based therapy in the frontline setting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback